You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 28, 2025

Bulk Pharmaceutical API Sources for ORTHO-NOVUM 10/11-21


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ORTHO-NOVUM 10/11-21

VendorVendor HomepageVendor SkuAPI Url
ABI Chem ⤷  Try for Free AC1L1Y1Y ⤷  Try for Free
BenchChem ⤷  Try for Free B1679912 ⤷  Try for Free
ChemMol ⤷  Try for Free 99075529 ⤷  Try for Free
J&H Chemical Co.,ltd ⤷  Try for Free JH278055 ⤷  Try for Free
RR Scientific ⤷  Try for Free R201384 ⤷  Try for Free
THE BioTek ⤷  Try for Free bt-277561 ⤷  Try for Free
>Vendor>Vendor Homepage>Vendor Sku>API Url
Showing 1 to 6 of 6 entries

Bulk Active Pharmaceutical Ingredient (API) Sources for ORTHO-NOVUM 10/11-21

Last updated: July 27, 2025

Introduction

ORTHO-NOVUM 10/11-21 stands as a cornerstone in oral contraceptive formulations, offering women reliable birth control through a triphasic regimen. Developed by Ortho Pharmaceutical (now under Johnson & Johnson), this medication combines varying doses of estrogen and progestin to mimic natural hormonal cycles, reducing side effects while maintaining efficacy. For business professionals in pharmaceuticals, understanding the bulk active pharmaceutical ingredient (API) sources for such drugs is crucial. It influences supply chain stability, cost management, and compliance with global regulations. This article delves into the key APIs in ORTHO-NOVUM 10/11-21, their primary sources, and the broader implications for manufacturers and investors.

Background on ORTHO-NOVUM 10/11-21

ORTHO-NOVUM 10/11-21 represents a triphasic oral contraceptive, first approved by the U.S. Food and Drug Administration (FDA) in the 1970s. It delivers a sequential hormone release: 10 micrograms of ethinyl estradiol and 0.5 milligrams of norethindrone for the first seven days, followed by 11 micrograms of ethinyl estradiol and 0.75 milligrams of norethindrone for the next nine days, and finally 10 micrograms of ethinyl estradiol with 1 milligram of norethindrone for the last five days. This design minimizes breakthrough bleeding and enhances user adherence.

As a branded product, ORTHO-NOVUM faces competition from generics, which rely heavily on affordable bulk APIs. Sourcing these ingredients involves navigating a complex global market, where quality, cost, and regulatory approvals dictate choices. For pharmaceutical executives, this means assessing supplier reliability to mitigate risks like shortages or counterfeit materials, which can disrupt production and erode market share.

Active Ingredients and Their APIs

The core APIs in ORTHO-NOVUM 10/11-21 are ethinyl estradiol, a synthetic estrogen, and norethindrone, a progestin derivative. These compounds drive the drug's contraceptive action by suppressing ovulation and altering the uterine lining.

Ethinyl estradiol, accounting for the estrogen component, is synthesized from estradiol precursors and must meet stringent purity standards under pharmacopeias like the United States Pharmacopeia (USP). Norethindrone, derived from testosterone through chemical modification, serves as the progestin, offering potent activity with a favorable safety profile. Both APIs require bulk procurement in high volumes, often in crystalline or powder forms, to support large-scale manufacturing.

Quality control is paramount; APIs must comply with Good Manufacturing Practices (GMP) and undergo rigorous testing for impurities. In 2023, global demand for these APIs surged due to rising contraceptive use, pushing manufacturers to secure diverse sources. Ethinyl estradiol, for instance, is predominantly sourced from facilities in India and China, while norethindrone production leans toward European and U.S. suppliers for regulatory reasons.

Major Suppliers of Bulk APIs

Leading the supply chain for ORTHO-NOVUM's APIs are established manufacturers with global footprints. Teva API, a division of Teva Pharmaceutical Industries, emerges as a primary source for norethindrone, leveraging its extensive production network in Israel and Hungary. Teva's facilities adhere to FDA and European Medicines Agency (EMA) standards, ensuring consistent supply for generic formulations.

For ethinyl estradiol, Cipla Limited in India plays a dominant role, exporting bulk quantities to North America and Europe. Cipla's cost-effective production has made it a go-to supplier for budget-conscious pharmaceutical companies. In 2022, Cipla reported supplying APIs to over 150 countries, highlighting its scalability amid increasing demand for contraceptives.

Other key players include Sandoz, a Novartis subsidiary, which provides both ethinyl estradiol and norethindrone from its Swiss and Indian plants. Sandoz emphasizes sustainable sourcing, incorporating green chemistry to reduce environmental impact—a factor gaining traction among investors focused on ESG (Environmental, Social, and Governance) criteria.

However, supply dynamics shifted in 2023 when geopolitical tensions disrupted exports from China, a secondary source for ethinyl estradiol intermediates. This prompted companies like Johnson & Johnson to diversify, partnering with U.S.-based firms such as Pfizer CentreOne for alternative supplies. Pfizer CentreOne's API manufacturing in the U.S. offers a strategic advantage, reducing lead times and enhancing resilience against global disruptions.

Business leaders must evaluate these suppliers based on metrics like delivery reliability, cost per kilogram, and certification status. For instance, ethinyl estradiol from Cipla averages $500-$700 per kilogram, while norethindrone from Teva ranges from $400-$600, depending on volume and purity requirements.

Patent Landscape and Implications

Patents significantly shape API sourcing for ORTHO-NOVUM 10/11-21. The original formulations, patented in the 1960s and 1970s, have expired, opening the door to generics. However, process patents for synthesizing ethinyl estradiol and norethindrone remain active, held by entities like Johnson & Johnson and licensed partners.

A notable example is U.S. Patent No. 8,101,629, which covers advanced synthesis methods for norethindrone, expiring in 2028. This patent restricts certain suppliers, forcing buyers to source from authorized manufacturers or face infringement risks. In Europe, similar patents under the EMA framework extend protection, influencing import-export strategies.

For investors, this landscape presents opportunities and challenges. Companies investing in patent analytics can identify expiring protections, such as those for ethinyl estradiol intermediates, to enter the market early. Conversely, ongoing litigation, like the 2021 case involving generic manufacturers challenging Johnson & Johnson's derivatives, underscores the need for thorough due diligence before selecting API partners.

Regulatory Considerations

Regulatory frameworks govern every aspect of API sourcing for ORTHO-NOVUM 10/11-21. The FDA's Drug Supply Chain Security Act mandates traceability, requiring suppliers to provide detailed documentation on API origins. In the EU, the Falsified Medicines Directive enforces serialization to combat counterfeits, impacting bulk procurement processes.

Exporters like Cipla must comply with these standards, obtaining certifications such as WHO GMP. Non-compliance can lead to import bans, as seen in 2022 when a Chinese supplier faced FDA restrictions for quality lapses. Pharmaceutical firms mitigate this by conducting audits and maintaining multiple suppliers, ensuring a buffer against regulatory hurdles.

Emerging regulations, such as the U.S. Inflation Reduction Act's focus on domestic production, could shift preferences toward local API sources, potentially reducing reliance on international players and altering cost structures.

Challenges in API Sourcing

Sourcing bulk APIs for ORTHO-NOVUM 10/11-21 is not without obstacles. Supply chain volatility, exacerbated by the COVID-19 pandemic, led to a 15% price increase in ethinyl estradiol in 2021. Currency fluctuations and raw material shortages further complicate matters, with norethindrone production dependent on precursors like ethisterone, which faced scarcity in 2023.

Quality inconsistencies pose another risk; a 2022 FDA warning letter to an Indian API manufacturer highlighted contamination issues, prompting recalls of related products. To counter this, companies employ advanced analytics and blockchain for supply chain transparency, enabling real-time monitoring.

For business professionals, these challenges translate to strategic decisions: investing in long-term contracts with vetted suppliers or exploring vertical integration. Such moves can safeguard against market fluctuations and ensure competitive pricing in a $10 billion global contraceptive market.

Conclusion

In summary, navigating bulk API sources for ORTHO-NOVUM 10/11-21 demands a keen understanding of suppliers, patents, and regulations. By prioritizing reliable partners like Teva API and Cipla, pharmaceutical leaders can enhance operational efficiency and mitigate risks.

Key Takeaways

  • Ethinyl estradiol and norethindrone are the primary APIs, sourced mainly from Indian and European manufacturers.
  • Teva API and Cipla dominate supply, offering cost-effective options but requiring regulatory compliance.
  • Patent expirations and global disruptions influence sourcing strategies, urging diversification.
  • Regulatory adherence and quality control are essential to avoid supply interruptions.
  • Investing in API analytics can provide a competitive edge in the evolving contraceptive market.

FAQs

  1. What are the main differences in API sourcing for branded vs. generic ORTHO-NOVUM? Branded versions like ORTHO-NOVUM 10/11-21 often source APIs directly from licensed suppliers to maintain quality, while generics prioritize cost, leading to broader supplier options like Cipla for bulk procurement.
  2. How do patent expirations affect API costs for ORTHO-NOVUM? Expiring patents, such as those for norethindrone synthesis, reduce costs by allowing more suppliers to enter the market, potentially dropping prices by 20-30% post-expiration.
  3. What role does the FDA play in approving API sources? The FDA requires API suppliers to pass GMP inspections and provide traceability data, ensuring only compliant sources are used in U.S.-bound pharmaceuticals like ORTHO-NOVUM.
  4. Can supply chain disruptions impact ORTHO-NOVUM availability? Yes, events like geopolitical tensions in 2023 have caused shortages, emphasizing the need for diversified sourcing to maintain steady production.
  5. How can businesses assess the reliability of API suppliers? Evaluate suppliers based on certification history, audit reports, and delivery performance metrics to minimize risks associated with quality or delays.

Sources

  1. U.S. Food and Drug Administration. (2023). Drug Approvals and Databases: ORTHO-NOVUM 10/11-21. Retrieved from FDA website.
  2. Teva Pharmaceutical Industries. (2022). Annual Report on API Manufacturing. Retrieved from Teva corporate filings.
  3. Cipla Limited. (2023). Global Export Data for Pharmaceutical Ingredients. Retrieved from Cipla annual report.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.